Gyre Therapeutics, Inc. GYRE EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Gyre Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s EBITDA margin?
- Gyre Therapeutics, Inc. (GYRE) reported EBITDA margin of 2.1% in Q1 2026.
- How has Gyre Therapeutics, Inc.'s EBITDA margin changed year-over-year?
- Gyre Therapeutics, Inc.'s EBITDA margin decreased by 82.3% year-over-year, from 12% to 2.1%.
- What is the long-term trend for Gyre Therapeutics, Inc.'s EBITDA margin?
- Over 4 years (2020 to 2025), Gyre Therapeutics, Inc.'s EBITDA margin has grown at a -54.2% compound annual growth rate (CAGR), from -273.2% to 12%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.